home / stock / clls / clls articles

CLLS Articles, Cellectis S.A. - From 11/01/23

Stock Information
Company Name: Cellectis S.A.
Stock Symbol: CLLS
Market: NASDAQ
Website: cellectis.com
Menu
CLLS CLLS Quote CLLS Short CLLS News CLLS Articles CLLS Message Board
Get CLLS Alerts

News, Short Squeeze, Breakout and More Instantly...
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge | Benzinga

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.55% to 3...
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected | Benzinga

U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow tr...

Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket | Benzinga

Gainers Cellectis S.A. (NASDAQ: CLLS) shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration and investment ...

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca | Benzinga

Collaboration leverages Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therap...
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Benzinga

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) --  Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneeri...

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress | Benzinga

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) --  Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneeri...

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1) | Benzinga

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Benzinga

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...

Previous 10 Next 10